<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36493498</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7727</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of radiology</Title><ISOAbbreviation>Eur J Radiol</ISOAbbreviation></Journal><ArticleTitle>Hypometabolic and hypermetabolic brain regions in patients with ALS-FTD show distinct patterns of grey and white matter degeneration: A pilot multimodal neuroimaging study.</ArticleTitle><Pagination><StartPage>110616</StartPage><MedlinePgn>110616</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejrad.2022.110616</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0720-048X(22)00466-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Up to 50% of amyotrophic lateral sclerosis (ALS) patients develop some degree of cognitive dysfunction and a small proportion of these develop frontotemporal dementia (FTD). Non-invasive techniques of magnetic resonance imaging (MRI) and [<sup>18</sup>F]-fluoro-2-deoxy-d-glucose (<sup>18</sup>F-FDG) positron emission tomography (PET) have demonstrated structural and metabolic abnormalities, respectively, in the brains of such patients with ALS-FTD. Although initial <sup>18</sup>F-FDG PET studies in ALS patients showed only hypometabolism of motor and extramotor brain regions, subsequent studies have demonstrated hypermetabolic changes as well. Such contrasting findings prompted us to hypothesize that hypo- and hypermetabolic brain regions in ALS-FTD patients are associated with divergent degeneration of structural grey matter (GM) and white matter (WM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cerebral glucose metabolic rate (CMR<sub>glc</sub>), cortical thickness (CT), fractal dimension (FD), and graph theory WM network analyses were performed on clinical MRI and <sup>18</sup>F-FDG PET images from 8 ALS-FTD patients and 14 neurologic controls to explore the relationship between GM-WM degeneration and hypo- and hypermetabolic brain regions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CMR<sub>glc</sub> revealed significant hypometabolism in frontal and precentral gyrus brain regions, with hypermetabolism in temporal, occipital and cerebellar regions. Cortical thinning was noted in both hypo- and hypermetabolic brain areas. Unlike CT, FD did not reveal widespread GM degeneration in hypo- and hypermetabolic brain regions of ALS-FTD patients. Graph theory analysis showed severe WM degeneration in hypometabolic but not hypermetabolic areas, especially in the right hemisphere.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our multimodal MRI-PET study provides insights into potentially differential pathophysiological mechanisms between hypo- and hypermetabolic brain regions of ALS-FTD patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Venkateswaran</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Electrical and Electronics Engineering, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad, 500078, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland, OH 44195, USA; Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: erik.pioro@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Eur J Radiol</MedlineTA><NlmUniqueID>8106411</NlmUniqueID><ISSNLinking>0720-048X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="Y">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS-FTD</Keyword><Keyword MajorTopicYN="N">Hypermetabolism</Keyword><Keyword MajorTopicYN="N">Hypometabolism</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">Multimodal</Keyword><Keyword MajorTopicYN="N">PET</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: &#x2018;The authors do not report any conflict of interest relevant to the present study. EPP has received clinical trial and/or research funding from the ALS Association, Biogen, Inc., Biohaven Pharmaceuticals, NIH/CDC, and the Samuel J. and Connie M. Frankino Charitable Foundation. He has received consulting fees from Argenx, Amylyx, Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Cytokinetics, Inc., ITF Pharma, Inc., MT Pharma America, Inc., Neurotherapia, Inc., and Otsuka America, Inc.&#x2019;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36493498</ArticleId><ArticleId IdType="doi">10.1016/j.ejrad.2022.110616</ArticleId><ArticleId IdType="pii">S0720-048X(22)00466-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>